Amarin Corporation plc - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
AMRN Nasdaq 2836 www.amarincorp.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Amarin Corporation plc

Amarin to Report Third Quarter 2026 Financial Results and Host Conference Call on October 28, 2026 - Oct 21st, 2026 6:00 am
European Equities Traded in the US as American Depositary Receipts Decline in Monday Trading - Oct 19th, 2026 9:13 am
FDA Expands ImmunityBio's Anktiva Label in Bladder Cancer - Oct 15th, 2026 9:56 am
Here's Why You Should Add EYPT Stock to Your Portfolio Now - Oct 15th, 2026 8:04 am
RARE's Fayuvi Approval Spurs Second PRV Sale Worth $203M in a Week - Oct 15th, 2026 7:33 am
LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label - Oct 14th, 2026 10:38 am
Here's Why You Should Add ANRO Stock to Your Portfolio Now - Oct 14th, 2026 6:59 am
Syndax Stock Falls 16% as Phase II Fibrosis Study Misses Primary Goal - Oct 14th, 2026 6:52 am
BMY Reports Mixed Phase III Trial Results, Stock Down - Oct 13th, 2026 10:40 am
Prime Medicine Stock Rallies Nearly 26% in a Month: Here's Why - Oct 12th, 2026 9:24 am
PMVP Stock Rises 19% in 3 Months: Here's What You Need to Know - Oct 12th, 2026 8:55 am
argenx Meets Primary Endpoint in Phase II Celiac Disease Study - Oct 9th, 2026 10:55 am
EDIT Set to Begin First-in-Human Study in Hypercholesterolemia - Oct 9th, 2026 8:53 am
Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio - Oct 9th, 2026 7:37 am
Here's Why You Should Add LPCN Stock to Your Portfolio Now - Oct 8th, 2026 7:57 am
ETON Stock Surges 108% in Six Months: Here's What You Need to Know - Oct 7th, 2026 9:08 am
Merck's Tulisokibart Meets Endpoints in Hidradenitis Suppurativa Study - Oct 1st, 2026 6:55 am
Teva's Branded Drugs Take Center Stage in Its Growth Strategy - Sep 29th, 2026 5:50 am
RHHBY's Lunsumio Combo Meets Goal in 2L Follicular Lymphoma Study - Sep 17th, 2026 8:48 am
RCKT Aligns With FDA on Completing Phase II Study in Danon Disease - Sep 16th, 2026 8:56 am